Navigation Links
AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
Date:2/11/2011

REDWOOD CITY, Calif., Feb. 11, 2011 – AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the pricing of its initial public offering of 8 million shares of common stock at $5.00 per share. All of the common stock will be sold by AcelRx.  In addition, AcelRx has granted to the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock from AcelRx to cover over-allotments, if any. The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol "ACRX" on February 11, 2011.

Piper Jaffray & Co. is acting as sole book-running manager and Cowen and Company, LLC, Canaccord Genuity Inc., and JMP Securities LLC are acting as co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on February 10, 2011. The offering is being made by means of a prospectus forming part of the effective registration statement, copies of which may be obtained, when available, by contacting Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by calling 1-800-747-3924.

About AcelRx Pharmaceuticals

Based in Redwood City, CA, AcelRx Pharmaceuticals (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab™ PCA System, which has completed Phase 2 clinical development, is designed to solve the problems associated with post-operative intravenous patient-co
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
2. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
3. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
6. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
7. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
10. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
11. Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Inc. (Pink sheets GATA.PK) The guidance contained ... provided to assist investors with the development of earnings ... represent the best estimate of management as to future ... such differences could be material.  These forecasts are subject ...
... BOSTON, March 2, 2012  Solos Endoscopy, Inc. (OTCPK: SNDY) ... completed, during the month of February, its Food and ... received a NAI (No Action Indicated) for the inspection. ... to periodically perform unannounced inspections for medical device manufacturers ...
Cached Medicine Technology:Groupe Athena, Inc. Clarifies Previous Guidance, Addresses U.S. Drug Shortage 2Groupe Athena, Inc. Clarifies Previous Guidance, Addresses U.S. Drug Shortage 3Solos Endoscopy, Inc. Successfully Completes Level I FDA Inspection 2
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
(Date:4/17/2014)... team led by Cesar A. Arias, M.D., Ph.D., at ... (UTHealth) has identified a new superbug that caused a ... in the April 17 issue of The New ... is part of a class of highly-resistant bacteria known ... is a major cause of hospital and community-associated infections. ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic ... had a 24 percent lower risk for prostate cancer. ... to use of the drug, or new ones that work ... from the foxglove plant, has been used for centuries in ...
... Using new genetic information, scientists have linked a commonly ... reduced risk of bladder cancer, according to findings presented ... 2-6, and simultaneously published in Cancer Prevention Research, a ... Jian Gu, Ph.D., assistant professor of epidemiology at ...
... SATURDAY, April 2 (HealthDay News) -- Researchers who sequenced ... patients identified more than 1,700 mutations, most of which ... explain why it,s difficult to predict breast cancer patient ... at Washington University in St. Louis and the Siteman ...
... By Jenifer Goodwin HealthDay Reporter , FRIDAY, ... temporarily zaps away forehead wrinkles by freezing the nerves ... The technique, if eventually approved by the U.S. Food ... and Dysport. Both are injectable forms of Botulinum toxin ...
... A new hedgehog pathway inhibitor demonstrated efficacy in ... basal cell nevus syndrome, a rare inheritable disease, according ... Annual Meeting 2011, held April 2-6. In 1996, ... of Oakland Research Institute, and colleagues identified the site ...
... (HealthDay News) -- It,s important to keep injury prevention in ... Greer, of the MCGHealth Sports Medicine Center in Augusta, Ga. ... All children should undergo a physical examination before they participate ... period of time, they should begin increasing their activity ...
Cached Medicine News:Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 2Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 3Health News:Genetic variation linked to longer telomeres and lower risk of bladder cancer 2Health News:Most Breast Tumors Have Unique Genetic 'Fingerprint,' Study Finds 2Health News:Freezing Wrinkles a Possible Alternative to Botox 2Health News:Freezing Wrinkles a Possible Alternative to Botox 3Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 2Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 3Health News:Tips for Keeping Young Athletes Safe 2
... pressure sensor and continues to lead ... only sensor on the market that ... significantly improved maneuverability and pushability, it ... as well as a valuable clinical ...
... its professional AED offeringthe G3 Pro. ... ECG color display, provides manual override ... most advanced technology available to provide ... for emergency treatment of sudden cardiac ...
... The Littmann Electronic Stethoscope Model 4100WS features ... technology allowing you to reduce ambient noise ... eliminating critical body sounds. Three frequency modes ... and other body sounds: Bell (20-200 Hz), ...
... is a 3D quantitative echo system ... exams are performed. Intelligent design and ... revolutionary clinical performance and workflow. The ... data streams simultaneously and incorporates a ...
Medicine Products: